Limited Offer
Adverse Events and Oncotargeted Kinase Inhibitors
- 1st Edition - May 8, 2017
- Author: Giuseppe Tridente
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 9 4 0 0 - 6
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 9 4 4 5 - 7
Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug clas… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.
A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.
This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.
- Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines
- Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs
- Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more
Intended for pharmacologists, clinicians and specialists including oncologists, drug safety control officials and drug developers and producers who are working to find effective molecules with the lowest adverse effects profiles; academics involved in drug safety issues and public health professionals
Part I: General Aspects
1. Introduction2. Protein and Lipid Kinases3. Kinase Inhibitors4. Adverse Events
Part II: Oncotargeted Kinase Inhibitors
5. Imatinib6. Gefitinib7. Erlotinib8. Sorafenib9. Sunitinib10. Dasatinib11. Lapatinib12. Nilotinib13. Pazopanib14. Vandetanib15. Vemurafenib16. Crizotinib17. Ruxolitinib18. Axitinib19. Bosutinib20. Regorafenib21. Cabozantinib22. Ponatinib23. Dabrafenib24. Trametinib25. Adatinib26. Idelalisib27. Ibrutinib
Part III: Overview
28. Kinase Inhibitors as Adverse Event Inducers29. Kinase Inhibitors as Drug Class Events30. Conclusion and Perspectives
- No. of pages: 736
- Language: English
- Edition: 1
- Published: May 8, 2017
- Imprint: Academic Press
- Hardback ISBN: 9780128094006
- eBook ISBN: 9780128094457
GT
Giuseppe Tridente
School of Medicine and Surgery
Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine
Universita degli Studi di Verona, Italy